Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase EARLY_PHASE1 2Phase 3 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Completed 55Recruiting 31Terminated 21Unknown 13Active not recruiting 9Not yet recruiting 6Withdrawn 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Dermatologic 1

Conditions

Brain Neoplasms 2Melanoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Temozolomide × Clear all
NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

University of Arizona

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00021307 2013-07-11

Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme

Fox Chase Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡